AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12435175
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and docetaxel combination treatment
Trial: 12435175
Drug: Poststudy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poststudy treatment with capecitabine
Trial: 12435175
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (capecitabine/docetaxel)
Trial: 8110697
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release acetazolamide (500 mg twice a day)
Trial: 113143
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg orally followed by TRH intravenously
Trial: 113143
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg orally followed by placebo injection
Trial: 113143
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet followed by TRH intravenously
Trial: 113143
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet followed by placebo injection
Trial: 27834619
Drug: Low-dose plyometric
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose plyometric training (PT), 60 foot contacts, twice-weekly for 6 weeks
Trial: 27834619
Drug: Low-dose plyometric
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose plyometric training (PT) in Mid-PHV group
Trial: 27834619
Drug: Low-dose plyometric
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose plyometric training (PT) in Pre-PHV group
Trial: 11722314
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT), 10 sessions including cognitive methods, behavioural methods, problem-solving skills training, and behavioural counselling to significant others.
Trial: 11722314
Drug: Routine medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical treatment (Control group)
Trial: 9393272
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment or information provided to the control group
Trial: 3259337
Drug: Thiopental (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (4.0 mg/kg)
Trial: 26183034
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (GDFT) with the LiDCOrapid system
Trial: 26183034
Drug: Routine fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid therapy (Control)
Trial: 20006169
Drug: Thermosetting gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermosetting gel containing 2.5% prilocaine and 2.5% lidocaine
Trial: 20006169
Drug: Thermosetting gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermosetting gel
Trial: 9874712
Drug: Low-dose thalidomide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thalidomide (200 mg, escalated to 1200 mg)
Trial: 9874712
Drug: High-dose thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose thalidomide (200 mg, escalated to 1200 mg)
Trial: 8911877
Drug: Flosequinan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan (100 mg daily)
Trial: 1806811
Drug: Oral DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DDAVP (150 to 600 micrograms/day)
Trial: 1806811
Drug: Intranasal DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DDAVP
Trial: 6441815
Drug: Prostaglandin synthetase
RxNorm normalized name: nitric oxide synthase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin synthetase promoter (263E) 500 mg three times daily
Trial: 31577678
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics for 24 hours
Trial: 31577678
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics for 72 hours
Trial: 27354766
Drug: Nebulized magnesium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulfate (MgSO4) and salbutamol combination
Trial: 24381294
Drug: fMRI decoding
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fMRI decoding of spoken words in one language (e.g., 'horse' in English)
Trial: 21706151
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) add-on to riluzole, initial dose of 2 IU s.c. every other day, progressively increased to a maximum of 8 IU.
Trial: 21706151
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) add-on to riluzole
Trial: 21203523
Drug: Alum-adjuvanted H5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted H5 VLP vaccine (5, 10, or 20 µg)
Trial: 21203523
Drug: Alum-adjuvanted H5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted H5 VLP vaccine (10 or 20 µg)
Trial: 21203523
Drug: Alum-adjuvanted H5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted H5 VLP vaccine (all doses)
Trial: 17882705
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone eyedrops
Trial: 12020141
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention program (11-week duration) including education, environmental modifications, exercise programs, drug regimen reviews, provision of hip protectors, and post-fall conferences.
Trial: 8570882
Drug: Low-dose ofloxacin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ofloxacin (OFLX) and erythromycin (EM) therapy daily for 6 months
Trial: 8570882
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment of OFLX and EM therapy for 6 months
Trial: 8570882
Drug: Erythromycin (EM)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin (EM) therapy for 6 months
Trial: 8570882
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (neither OFLX nor EM therapy)
Trial: 30173058
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT)
Trial: 21434340
Drug: Chaipo Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaipo Granule (CPG) 3 pouches twice a day for 24 weeks
Trial: 21434340
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (salmeterol and fluticasone propionate, salbutamol + ipratropium bromide)
Trial: 19842560
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (2‐4 U/h)
Trial: 19842560
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy (no insulin administration)
Trial: 14593127
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (including percutaneous transluminal angioplasty, balloon-expandable stent, self-expandable stent)
Trial: 10924782
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A/B vaccine (Twinrix Adult)
Trial: 10924782
Drug: Monovalent vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent vaccines (Havrix 1440+Engerix‐B or Vaqta+Gen H‐B‐Vax)
Trial: 1583173
Drug: Calcipotriol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (50 micrograms/gm) ointment
Trial: 1583173
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate (1 mg/gm) ointment
Trial: 25475247
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine rehabilitation (IMR) group receiving acupuncture and Chinese herbs in addition to basic Western medicine and rehabilitation treatment.
Trial: 25475247
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation (CR) group not receiving acupuncture and Chinese herbal medicine.
Trial: 25475247
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine rehabilitation (IMR) group
Trial: 20823897
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (5‐formyltetrahydrofolate) at a dosage of 70 μg/kg/day for 2 weeks
Trial: 20823897
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no folinic acid treatment)
Trial: 18257178
Drug: Cisapride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 10 mg orally, three times a day.
Trial: 15694243
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drug exposure)
Trial: 9223023
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg, qid) in REFLUX-group (N = 43)
Trial: 9223023
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg, tid) in REFLUX-group (N = 43)
Trial: 9223023
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg, qid) in DYSPEPSIA-group (N = 84)
Trial: 9223023
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg, tid) in DYSPEPSIA-group (N = 84)
Trial: 9223023
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (Cisapride and Domperidone)
Trial: 8354325
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 5 mg, inhaled four times a day for 3 weeks
Trial: 8354325
Drug: Placebo, inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, inhaled four times a day for 3 weeks
Trial: 31495952
Drug: 0.025 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg/kg teduglutide
Trial: 31495952
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg teduglutide
Trial: 27852236
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) 200 mg
Trial: 11177199
Drug: HIFAT (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFAT (1.2 g saturated fat/kg BM with 3500 U heparin intravenously)
Trial: 11177199
Drug: CHO (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (2.5 g carbohydrate/kg BM)
Trial: 11177199
Drug: NA (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA (2.5 g carbohydrate + 20 mg nicotinic acid/kg BM)
Trial: 1482131
Drug: Antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic combination therapy (beta-lactam plus aminoglycoside)
Trial: 1482131
Drug: Monotherapy (beta-lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (beta-lactam or aminoglycoside)
Trial: 4018499
Drug: Cimetidine bolus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine bolus administration (up to 300 mg every 6 h, 1200 mg/day)
Trial: 4018499
Drug: Cimetidine primed
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine primed infusion (up to 50 mg/h, 1200 mg/day)
Trial: 4018499
Drug: Cimetidine infusion
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine infusion
Trial: 29036480
Drug: Mandible advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandible advanced device (MAD) therapy
Trial: 29036480
Drug: Group OSAHS
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group OSAHS (induced OSAHS without treatment)
Trial: 27343983
Drug: Cell culture-derived
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell culture-derived trivalent influenza vaccine (TIVc)
Trial: 27343983
Drug: Egg-derived trivalent
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-derived trivalent influenza vaccine (TIV)
Trial: 25045360
Drug: Patient-based combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-based combined symptom medication score
Trial: 18826358
Drug: Cyclosporine (1.25-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (1.25-5 mg/kg/day) administered intravenously, initiated within 8 hours of injury, in 2 divided doses or continuous infusion over 72 hours.
Trial: 18826358
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, initiated within 8 hours of injury.
Trial: 16193496
Drug: Levalbuterol (LEV)
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levalbuterol (LEV) 0.31 mg
Trial: 16193496
Drug: Levalbuterol (LEV)
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levalbuterol (LEV) 0.63 mg
Trial: 16193496
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (RAC) 1.25 mg (for children <33 lb)
Trial: 16193496
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (RAC) 2.5 mg (for children >/=33 lb)
Trial: 10359887
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate powder, 500 microgram, twice daily
Trial: 7677297
Drug: Resistance to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance to thyroid hormone
Trial: 2371802
Drug: Propofol in
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol in emulsion (Diprivan) - bolus of 2 mg/kg followed by infusion of 6 mg/kg/h for one hour.
Trial: 2371802
Drug: Intralipid 10%
RxNorm normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 10% - bolus of 0.2 mg/kg followed by infusion of 0.6 ml/kg/h for one hour.
Trial: 6164204
Drug: Dihydroergotamin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamin and low-dose heparin (DHEH)
Trial: 31404668
Drug: Reslizumab 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reslizumab 3.0 mg/kg (more than 12 months exposure)
Trial: 25392071
Drug: Atorvastatin (n=255)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (n=255)
Trial: 12955096
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg octreotide administered subcutaneously at 2245
Trial: 26402918
Drug: LCZ696 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 200 mg, increased to 400 mg if uncontrolled after 2 weeks, with optional addition of another antihypertensive drug after 4 weeks (n=21)
Trial: 24821628
Drug: L-bent-level gesture
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-bent-level gesture
Trial: 18594000
Drug: nab-paclitaxel (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (260 mg/m² as a 30-minute infusion)
Trial: 18594000
Drug: sb-paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sb-paclitaxel (175 mg/m² as a 3-hour infusion)
Trial: 7721556
Drug: Daily baths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily baths in the Dead Sea (Group 1, n = 9)
Trial: 7721556
Drug: Daily sulphur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sulphur baths (Group 2, n = 9)
Trial: 7721556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of daily Dead Sea bathing and sulphur baths (Group 3, n = 10)
Trial: 30378759
Drug: PLGM threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLGM threshold at 90 mg/dL during exercise
Trial: 30378759
Drug: PLGM threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLGM threshold at 70 mg/dL during exercise
Trial: 15608053
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (zidovudine/lamivudine and efavirenz)
Trial: 15608053
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (zidovudine/lamivudine/abacavir and efavirenz)
Trial: 2108751
Drug: Erythropoietin to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin to achieve a haemoglobin concentration of 95‐110 g/l (n = 40)
Trial: 2108751
Drug: Erythropoietin to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin to achieve a haemoglobin concentration of 115‐130 g/l (n = 38)
Trial: 7352279
Drug: Buprenorphine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (4 mg/day)
Trial: 28235249
Drug: Secukinumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (both doses)
Trial: 21561791
Drug: Intermittent androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent androgen deprivation therapy (IAD)
Trial: 21561791
Drug: Continuous androgen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous androgen deprivation therapy (CAD)
Trial: 25622671
Drug: 0.50 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 µg calcitriol daily
Trial: 25622671
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (original treatment regimen)
Trial: 12833245
Drug: Intravenous pulses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulses of methylprednisolone (MEP)
Trial: 12833245
Drug: Gold standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard dose of 1 g/day for 3 consecutive days of MEP
Trial: 12833245
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of MEP
Trial: 10036892
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B, n = 13)
Trial: 10036892
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C, n = 13)
Trial: 10036892
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B)
Trial: 10036892
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C)
Trial: 8694599
Drug: Heparin-bonded circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded circuits (HBC) with lower anticoagulation therapy (activated clotting time > 280 seconds)
Trial: 8694599
Drug: Heparin-bonded circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded circuits (HBC) with lower anticoagulation therapy
Trial: 8694599
Drug: Conventional, nonheparin-bonded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, nonheparin-bonded circuits with full anticoagulation therapy (activated clotting time > 480 seconds)